

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cutia Therapeutics

科笛集团

(Incorporated in Cayman Islands with limited liability)

(Stock code: 2487)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of Cutia Therapeutics (the “**Company**”) hereby announces that a meeting of the Board will be held on Monday, 31 August 2026, for the purpose of, among other matters, considering and approving the interim results of the Company and its subsidiaries for the six months ended 30 June 2026 and its publication, considering the recommendation of payment of an interim dividend (if any) and transacting any other business.

By Order of the Board

Cutia Therapeutics

Zhang Lele

Chief Executive Officer and Executive Director

Hong Kong, 19 August 2026

As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Mr. Lu Minfang and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Zhang Zhisong and Mr. Ye Xiaoxiang as independent non-executive directors.